Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
A study of veterans also found, as other studies have, that treating the virus helps mitigate the risk of cardiovascular disease.
A European study of nearly 19,000 people with HIV also found that curing hep C was not associated with heart disease or non-AIDS cancer.
Direct-acting antivirals lower the risk of cardiovascular disease to a greater extent than interferon-based regimens.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
Direct-acting antivirals lower this risk to a greater extent than interferon-based regimens.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
Conditions such as autoimmune disorders, insulin resistance and cardiovascular disease tend to have a better outlook.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
A look at the link between hepatitis C and heart disease.
Among the hep C population, other factors associated with chronic kidney disease include being older and having diabetes or HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.